These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 23141475)

  • 1. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
    Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
    Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG; Kirsztajn GM
    J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alternative pathway of complement and the thrombotic microangiopathies.
    Teoh CW; Riedl M; Licht C
    Transfus Apher Sci; 2016 Apr; 54(2):220-31. PubMed ID: 27160864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.
    Riedl M; Fakhouri F; Le Quintrec M; Noone DG; Jungraithmayr TC; Fremeaux-Bacchi V; Licht C
    Semin Thromb Hemost; 2014 Jun; 40(4):444-64. PubMed ID: 24911558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N; Ayer M; Ergen A; Ozturk S
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical grand rounds: atypical hemolytic uremic syndrome.
    Hodgkins KS; Bobrowski AE; Lane JC; Langman CB
    Am J Nephrol; 2012; 35(5):394-400. PubMed ID: 22517061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD
    Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab therapy.
    Cataland SR
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
    [No Abstract]   [Full Text] [Related]  

  • 15. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.
    Giordano M; Castellano G; Messina G; Divella C; Bellantuono R; Puteo F; Colella V; Depalo T; Gesualdo L
    Pediatrics; 2012 Nov; 130(5):e1385-8. PubMed ID: 23027168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.
    Wilson CH; Brown AL; White SA; Goodship TH; Sheerin NS; Manas DM
    Transplantation; 2011 Oct; 92(8):e42-3. PubMed ID: 21989273
    [No Abstract]   [Full Text] [Related]  

  • 19. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
    Vaisbich MH; Henriques Ldos S; Watanabe A; Pereira LM; Metran CC; Malheiros DA; Modanez F; Silva JD; Vieira S; Macedo AC; Massarope B; Furusawa EA; Schvartsman BG
    J Bras Nefrol; 2013; 35(3):237-41. PubMed ID: 24100744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.